NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis → Trump just won 2024 (From Porter & Company) (Ad) Free PYPD Stock Alerts $5.00 +0.23 (+4.82%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$4.80▼$5.0950-Day Range$4.25▼$5.9552-Week Range$3.57▼$13.48Volume8,730 shsAverage Volume6,299 shsMarket Capitalization$24 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PolyPid alerts: Email Address PolyPid MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside184.0% Upside$14.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.72) to ($2.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector785th out of 927 stocksSurgical & Medical Instruments Industry80th out of 92 stocks 3.5 Analyst's Opinion Consensus RatingPolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePolyPid has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 60.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYPD. Previous Next 2.4 News and Social Media Coverage News SentimentPolyPid has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PolyPid this week, compared to 1 article on an average week.MarketBeat Follows1 people have added PolyPid to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.47% of the stock of PolyPid is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PolyPid are expected to grow in the coming year, from ($3.72) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About PolyPid Stock (NASDAQ:PYPD)PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.Read More PYPD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYPD Stock News HeadlinesMay 1, 2024 | globenewswire.comPolyPid to Participate in Citizens JMP Life Sciences ConferenceApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline PotentialMay 1, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 30, 2024 | globenewswire.comPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsApril 24, 2024 | msn.comPYPD: Polypid is Enhancing Surgical OutcomesApril 24, 2024 | globenewswire.comPolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024April 18, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceMay 1, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?February 15, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningFebruary 14, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 12, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialFebruary 12, 2024 | finance.yahoo.comPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialJanuary 31, 2024 | finance.yahoo.comPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024January 5, 2024 | msn.comWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 5, 2024 | msn.comCyclacel Pharmaceuticals, Angiodynamic among healthcare moversJanuary 4, 2024 | uk.finance.yahoo.comPolyPid Ltd. (PYPD)January 4, 2024 | msn.comPolyPid looks to raise $16.2M through private placementJanuary 4, 2024 | finance.yahoo.comPolyPid Announces Private Placement for $16 Million in Gross ProceedsNovember 12, 2023 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | investing.comEarnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trialNovember 8, 2023 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | benzinga.comPolyPid's Earnings: A PreviewSee More Headlines Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today5/01/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PYPD CUSIPN/A CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees59Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.6823) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-450.37% Return on Assets-101.27% Debt Debt-to-Equity Ratio2.17 Current Ratio0.83 Quick Ratio0.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-3.76Miscellaneous Outstanding Shares4,800,000Free Float3,612,000Market Cap$22.91 million OptionableNo Data Beta1.41 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Dikla Czaczkes Akselbrad (Age 51)CEO & Director Comp: $347.88kMr. Jonny Missulawin (Age 37)Chief Financial Officer Comp: $186.96kMs. Dalit Hazan (Age 53)Executive Vice President of R&D and Clinical & Regulatory Affairs Comp: $272.38kMr. Ori Warshavsky (Age 46)Chief Operating Officer - US Comp: $340.89kMs. Maria RubinVice President of OperationsMr. Tal VilnaiGeneral Counsel & Corporate SecretaryMs. Rivi Lev-ariVice President of Human ResourceDr. Jean-Marc Hagai Pharm.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsInspira Technologies Oxy B.H.N.NASDAQ:IINNNephrosNASDAQ:NEPHT2 BiosystemsNASDAQ:TTOOPAVmedNASDAQ:PAVMFemasysNASDAQ:FEMYView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 415,800 shares on 4/25/2024Ownership: 8.668%View All Institutional Transactions PYPD Stock Analysis - Frequently Asked Questions Should I buy or sell PolyPid stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PYPD shares. View PYPD analyst ratings or view top-rated stocks. What is PolyPid's stock price target for 2024? 1 equities research analysts have issued 12 month target prices for PolyPid's stock. Their PYPD share price targets range from $14.00 to $14.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 184.0% from the stock's current price. View analysts price targets for PYPD or view top-rated stocks among Wall Street analysts. How have PYPD shares performed in 2024? PolyPid's stock was trading at $3.80 on January 1st, 2024. Since then, PYPD stock has increased by 29.7% and is now trading at $4.93. View the best growth stocks for 2024 here. Are investors shorting PolyPid? PolyPid saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 1,300 shares, a decline of 60.6% from the March 31st total of 3,300 shares. Based on an average trading volume of 3,300 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company's shares are short sold. View PolyPid's Short Interest. When is PolyPid's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PYPD earnings forecast. How can I listen to PolyPid's earnings call? PolyPid will be holding an earnings conference call on Wednesday, May 8th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) issued its quarterly earnings results on Wednesday, February, 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80. When did PolyPid's stock split? PolyPid shares reverse split on the morning of Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO). When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. Who are PolyPid's major shareholders? PolyPid's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (8.67%). How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYPD) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.